Mercury From Seafood Not Tied to Brain Neuropathology

This article originally appeared here.
Share this content:
Mercury From Seafood Not Tied to Brain Neuropathology
Mercury From Seafood Not Tied to Brain Neuropathology

TUESDAY, Feb. 2, 2016 (HealthDay News) -- Seafood consumption is associated with increased brain levels of mercury, but these levels are not associated with brain neuropathology, according to a study published in the Feb. 2 issue of the Journal of the American Medical Association.

Martha Clare Morris, Sc.D., from the Rush University Medical Center in Chicago, and colleagues examined the correlation between seafood consumption and brain mercury levels and brain neuropathies. They analyzed autopsied brains of 554 deceased participants from the Memory and Aging Project clinical neuropathological cohort study (mean age at death, 89.9 years). A food-frequency questionnaire conducted at a mean of 4.5 years before death was used to examine seafood intake.

The researchers observed a positive correlation for brain mercury levels with the number of seafood meals consumed per week (P = 0.02). Seafood consumption (at least one meal/week) correlated with less Alzheimer's disease pathology among apolipoprotein E ε4 carriers, including lower density of neuritic plaques, less severe and widespread neurofibrillary tangles, and lower neuropathologically-defined Alzheimer's disease, after adjustment for age sex, education, and total energy intake. There was a correlation for higher intake levels of α-linolenic acid with lower odds of cerebral macroinfarctions. There was no correlation for higher brain concentrations of mercury with increased levels of brain neuropathy.

"Although seafood consumption was also correlated with higher brain levels of mercury, these levels were not correlated with brain neuropathology," the authors write.

Abstract
Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths